CJC-1295 (No DAC), Ipamorelin 10mg (Blend)

CJC-1295 (No DAC), Ipamorelin 10mg (Blend) is supplied as a research peptide blend in a sealed sterile glass vial. Each batch undergoes analytical verification to confirm molecular identity, composition, and purity prior to release.

In scientific literature, CJC-1295 (No DAC) has been investigated for interaction with growth hormone releasing hormone receptors, while Ipamorelin has been studied as a selective ghrelin receptor agonist influencing growth hormone secretion pathways. When evaluated together in research environments, these peptides have been examined for their coordinated influence on pulsatile growth hormone signaling.

Human endocrine studies involving related compounds have reported measurable increases in circulating growth hormone and insulin-like growth factor 1 biomarkers during supervised clinical investigations. Researchers often evaluate this combination to observe the interaction between hypothalamic signaling, pituitary hormone release, and downstream endocrine pathway activity.

This blend has been investigated in hormonal rhythm research, growth hormone axis signaling studies, and experimental models examining endocrine pathway modulation and metabolic signaling interactions.

All reported findings originate from structured laboratory or regulated human clinical research environments. These outcomes reflect observed biomarker and pathway changes under controlled conditions and are not established therapeutic claims.

This product is provided exclusively for scientific research and laboratory development purposes. It is not approved for human consumption, medical treatment, or diagnostic application. Researchers are responsible for ensuring compliance with applicable laws and regulatory standards governing acquisition and use.